Zykadia (ceritinib) — United Healthcare
Erdheim-Chester Disease
Initial criteria
- Diagnosis of Erdheim-Chester Disease
- AND Disease is positive for ALK rearrangement
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Zykadia therapy
Approval duration
12 months